PATHOLOGICAL BIOMINERALIZATION IN OVARIAN TUMORS

Chyzhma R. A., Bidenko M. V., Nykolenko A. P., Piddubnyi A. M., Moskalenko R. A.

LITERATURE REVIEWS

Scentific article

In 2018, 3,539 new cases of malignant ovarian neoplasms and 1,808 related deaths were registered in Ukraine. The one-year survival rate for ovarian cancer patients is 65 %, while the three-year and five-year survival rates are 40 % and 32 %, respectively. The aim of the work is to analyze the scientific literature to estimate the prevalence, mechanisms of development and diagnostic value of pathological biomineralization (PBM) in ovarian tumors. Calcification is one of the clinical features of ovarian cancer. Approximately 8% of cases are diagnosed by computed tomography. PBM in ovarian tumors can be divided into 2 groups: calcification of the tumor parenchyma, capsule or stroma and biomineralization as psammoma bodies (PB). Calcification of the ovarian cancer parenchyma is a secondary change in tumor tissue due to the secretion of collagen and direct effect of hormones. Nevertheless, the PBM development in the ovarian capsule, stroma or PB is one of the possible protective responses of tissues to the tumor spread and invasive growth. The presence of PT is a reliable pathognomonic sign of malignant ovarian tumors and can be identified both by instrumental diagnostic tests (ultrasound, CT and MRI) and histology. Also, the presence of biominerals contributes to an increase of five-year survival rates for patients with ovarian tumors up to 50%. The study of the chemical composition of calcifications of serous ovarian tumors by various methods showed the presence of inorganic elements such as aluminum (Al), cadmium (Cd), potassium (K), cobalt (Co), chromium (Cr), iron (Fe), zinc (Zn) and copper (Cu), magnesium (Mg) and sodium (Na). It was found that Calcium (Ca) and phosphorus (P) formed the biomineral basis of ovarian tumor calcifications. It has also been found that biomarkers of mineralization such as BMP-2, OPN, Runx2 and Osterix were also involved in pathological calcification in serous ovarian carcinomas. It was shown that ovarian tumors PBM development involves a few different mechanisms. It may indicate a link between the tumor stage and the diagnostic value of calcifications in ovarian tumors, as well as the subsequent prognosis of this disease. There is also a variation in the prevalence of calcification in different histological types of ovarian tumors. PBM is detected predominantly in the serous ovarian adenocarcinoma. However, for serous adenocarcinoma with a large number of PB, a separate nosology, “Psammocarcinoma”, was identified. It is obvious that the small calcifications (less than 200 μm) are not detected by radiology. That is why their detection occurs most often with histology. However, there is a lack of information on the prevalence of PBM in ovarian tumors, which would be based on a detailed histological and histochemical study.

ovarian tumors, pathological biomineralization, psammoma bodies, biomarkers.

1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-99.
2. Fedorenko ZP, Mykhailovych YuI, Hulak LO. Rak v Ukraini, 2018-2019. Biuleten natsionalnoho kantser-reiestru Ukrainy. 2020;21:60-1. [in Ukrainian].
3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32.
4. Mihanovskii AA, Kochina ML, Kharchenko YuV, Fedorenko NV, Schit NM. Analysis of the Results of Combined Treatment of Ovarian Cancer Patients. 2018;3(2):93-100.
5. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, Sant M. Eurocare Working Group. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012 Apr;51(4):441-53.
6. Vo C, Carney ME. Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am. 2007 Dec;34(4):687-700.
7. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):47-54.
8. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-99.
9. Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32.
10. Yoneda A, Lendorf ME, Couchman JR, Multhaupt HA. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 2012 Jan;60(1):9-21.
11. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep;177(3):1053-64.
12. Thomakos N, Diakosavvas M, Machairiotis N, Fasoulakis Z, Zarogoulidis P, Rodolakis A. Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. Cancers (Basel). 2019 Jul;24.11(8):1044.
13. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003 Mar-Apr;13(2):125-9.
14. Moskalenko R, Romaniuk A. Pathological biomineralization of soft tissues: monograph. Sumy: Sumy State University; 2020. 127 p.
15. Silva EG, Deavers MT, Parlow AF, Gershenson DM, Malpica A. Calcifications in ovary and endometrium and their neoplasms. Mod Pathol. 2003 Mar;16(3):219-22.
16. Wen J, Zhao Z, Huang L, Li L, Li J, Zeng Y, et al. Switch of the ovarian cancer cell to a calcifying phenotype in the calcification of ovarian cancer. J Cancer. 2018 Feb 28;9(6):1006-16.
17. Ganeshan D, Bhosale P, Wei W. Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY). 2016;41(8):1589-95.
18. Das DK. Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagn Cytopathol. 2009 Jul;37(7):534-41.
19. Wen J, Miao Y, Wang S, Tong R, Zhao Z, Wu J. Calcification: A Disregarded or Ignored Issue in the Gynecologic Tumor Microenvironments. Int J Gynecol Cancer. 2018 Mar;28(3):486-92.
20. Moskalenko RA. Biomineralizatsiia u tkanynakh liudskoho orhanizmu. Aktualni problemy suchasnoi medytsyny. Visnyk Ukrainskoi medychnoi stomatolohichnoi akademii. 2017;17(1(57)):308-13. [in Ukrainian].
21. Fanl M, Changqiu W, Yan L. Psammoma bodies in two types of human ovarian tumours: a mineralogical study. Miner Petrol. 2015;109:357-65.
22. Okada S, Ohaki Y, Inoue K, Kawamura T, Hayashi T, Kato T, Kumazaki T. Calcifications in mucinous and serous cystic ovarian tumors. J Nippon Med Sch. 2005 Feb;72(1):29-33.
23. Hudelist G, Singer CF, Kubista E, Manavi M, Mueller R, Pischinger K, Czerwenka K. Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization. Histopathology. 2004 Dec;45(6):633-7.
24. Breitschwerdt EB, Sontakke S, Cannedy A, Hancock SI, Bradley JM. Infection with Bartonella weissii and detection of Nanobacterium antigens in a North Carolina beef herd. J. Clin. Microbiol. 2001;39:879-82.
25. Olivera Merlin PS, Leyva Bohorquez Pdel C, Martínez-Cruz R, Pina Canseco S, Hernandez P, Martínez-Cruz M, et al. A study on inorganic elements in psammomas from ovarian & thyroid cancer. Indian J Med Res. 2012;135(2):217-20.
26. Maki M, Hirota S, Kaneko Y, Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int. 2000 Jul;50(7):531-5.
27. Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018 Mar 2;9(3):356.
28. Wang ZQ, Keita M, Bachvarova M, Gobeil S, Morin C, Plante M, et al. Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One. 2013 Oct 4;8(10):e74384.
29. Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, Matei D. β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 2015 Apr 30;34(18):2297-308.
30. Gilks CB, Bell DA, Scully RE. Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol. 1990;9:110-21.
31. Rieznik AV, Hapchenko AV, Hapchenko VV, Starkiv MP, Moskalenko RA. Ultrazvukove ekho biomineralizatsii shchytopodibnoi zalozy. J. Clin. Exp. Med. Res. 2015;3(2):188-98. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 4 (158), 2020 year, 43-48 pages, index UDK 616.441–003.84–02-07

10.29254/2077-4214-2020-4-158-43-48